{
    "clinical_study": {
        "@rank": "122691", 
        "arm_group": {
            "arm_group_label": "FTC/TDF for PrEP", 
            "description": "HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and\n      following seroconversion, assess the frequency of HIV-1 screening and screening method(s)\n      used for evaluation of seroconverters, and collect information regarding whether the\n      seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the\n      time of seroconversion."
        }, 
        "brief_title": "A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada\u00ae for Pre-Exposure Prophylaxis (PrEP)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participant in a FTC/TDF PrEP demonstration project or FTC/TDF for PrEP clinical\n             study\n\n          -  HIV-1 negative adults (any sex/gender, including transgender) \u2265 18 years of age at\n             time of enrollment in the demonstration project or clinical study.\n\n          -  Evidence of seroconversion while receiving FTC/TDF for PrEP\n\n        Exclusion Criteria:\n\n          -  This is an observational nested study and will monitor all reported seroconversions\n             without intervention/exclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "One hundred fifty (150) HIV-1 negative adults (any sex/gender, including transgender) and\n        \u2265 18 years of age who seroconvert while taking FTC/TDF for PrEP."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01902472", 
            "org_study_id": "GS-US-276-0103"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV-1", 
            "Truvada", 
            "FTC/TDF", 
            "Pre-exposure prophylaxy", 
            "PrEP", 
            "Resistance"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Foster City", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94404"
                }, 
                "name": "Gilead Sciences, Inc."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada\u00ae for Pre-Exposure Prophylaxis (PrEP)", 
        "overall_contact": {
            "email": "rebecca.guzman@gilead.com", 
            "last_name": "Rebecca Guzman"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Keith Rawlings, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Seroconversion rate among all subjects exposed to emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF) (Truvada\u00ae) for a PrEP indication", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }, 
            {
                "measure": "Proportion of seroconverters with resistance mutations", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }, 
            {
                "measure": "Proportion of seroconverters with signs/symptoms at or before seroconversion", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Year 3"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01902472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}